BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24788216)

  • 1. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.
    Minar P; Haberman Y; Jurickova I; Wen T; Rothenberg ME; Kim MO; Saeed SA; Baldassano RN; Stephens M; Markowitz J; Rosh J; Crandall WV; Heyman MB; Mack DR; Griffiths AM; Baker SS; Hyams JS; Kugathasan S; Denson LA
    Inflamm Bowel Dis; 2014 Jun; 20(6):1037-48. PubMed ID: 24788216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.
    Minar P; Jackson K; Tsai YT; Sucharew H; Rosen MJ; Denson LA
    Inflamm Bowel Dis; 2017 Dec; 24(1):198-208. PubMed ID: 29272485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy.
    Minar P; Jackson K; Tsai YT; Rosen MJ; Northcutt M; Khodoun M; Finkelman FD; Denson LA
    Inflamm Bowel Dis; 2016 Nov; 22(11):2641-2647. PubMed ID: 27749455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease.
    Therrien A; Chapuy L; Bsat M; Rubio M; Bernard G; Arslanian E; Orlicka K; Weber A; Panzini BP; Dorais J; Bernard EJ; Soucy G; Bouin M; Sarfati M
    Clin Exp Immunol; 2019 Feb; 195(2):251-264. PubMed ID: 30347439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?
    Turner D; Levine A; Walters TD; Focht G; Otley A; López VN; Koletzko S; Baldassano R; Mack D; Hyams J; Griffiths AM
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):254-260. PubMed ID: 27050050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
    Zollner A; Schmiderer A; Reider SJ; Oberhuber G; Pfister A; Texler B; Watschinger C; Koch R; Effenberger M; Raine T; Tilg H; Moschen AR
    J Crohns Colitis; 2021 Jan; 15(1):43-54. PubMed ID: 32556317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
    Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
    Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics.
    Tillinger W; Jilch R; Jilma B; Brunner H; Koeller U; Lichtenberger C; Waldhör T; Reinisch W
    Am J Gastroenterol; 2009 Jan; 104(1):102-9. PubMed ID: 19098857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
    Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease.
    Osterman MT; Gordon IO; Davis EM; Ciorba M; Glover SC; Abraham B; Khan F; Guo X; Yee EU; Allard FD; Claggett B; Shen B; Liu JJ
    Inflamm Bowel Dis; 2020 Sep; 26(10):1554-1561. PubMed ID: 31553433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
    Boon GJ; Day AS; Mulder CJ; Gearry RB
    World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil CD64 expression levels in IGRA-positive individuals distinguish latent tuberculosis from active disease.
    Corrêa RDS; Rodrigues LS; Pereira LHL; Nogueira OC; Leung J; Sousa MDS; Hacker MA; Siqueira HR; Capone D; Alves RLR; Pessolani MCV; Schmitz V; Pereira GMB
    Mem Inst Oswaldo Cruz; 2019; 114():e180579. PubMed ID: 30970080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
    Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
    Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease.
    Cozijnsen MA; Ben Shoham A; Kang B; Choe BH; Choe YH; Jongsma MME; Russell RK; Ruemmele FM; Escher JC; de Ridder L; Koletzko S; Martín-de-Carpi J; Hyams J; Walters T; Griffiths A; Turner D
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):133-140.e1. PubMed ID: 30981008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.